Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update - PubMed

Review

Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update

Annette Czernik et al. Autoimmunity. 2012 Feb.

Free article

Abstract

High-dose intravenous immunoglobulin (IVIg) is being increasingly utilized as an off-label therapy for a variety of autoimmune and inflammatory conditions across various specialties. Numerous reports have shown that it is an effective treatment for autoimmune skin blistering disorders. Unlike most therapies for blistering disorders, IVIg is not immunosuppressive and has a favorable side effect profile. This has allowed its use to expand dramatically over the last decade. However, due to the rarity and severity of autoimmune skin blistering diseases, well-designed prospective trials are generally lacking. This work highlights major research developments and the best evidence to date regarding the treatment of autoimmune pemphigus, bullous pemphigoid, mucous membrane pemphigoid, epidermolysis bullosa acquisita, pemphigoid gestationis, and linear IgA dermatosis with IVIg, providing an update on its efficacy, proposed mechanisms of action, side effect profile, and indications for use.

Similar articles

• High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases.

  Segura S, Iranzo P, Martínez-de Pablo I, Mascaró JM Jr, Alsina M, Herrero J, Herrero C. Segura S, et al. J Am Acad Dermatol. 2007 Jun;56(6):960-7. doi: 10.1016/j.jaad.2006.06.029. Epub 2007 Mar 21. J Am Acad Dermatol. 2007. PMID: 17368865

• A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders.

  Jolles S. Jolles S. Clin Exp Dermatol. 2001 Mar;26(2):127-31. doi: 10.1046/j.1365-2230.2001.00779.x. Clin Exp Dermatol. 2001. PMID: 11298100 Review.

• A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: Special focus on indication and combination therapy.

  Kianfar N, Dasdar S, Daneshpazhooh M, Aryanian Z, Goodarzi A. Kianfar N, et al. Exp Dermatol. 2023 Jul;32(7):934-944. doi: 10.1111/exd.14829. Epub 2023 May 7. Exp Dermatol. 2023. PMID: 37150538 Review.

• The use of intravenous immunoglobulin in autoimmune bullous diseases.

  Chee SN, Murrell DF. Chee SN, et al. Immunol Allergy Clin North Am. 2012 May;32(2):323-30, viii. doi: 10.1016/j.iac.2012.04.012. Epub 2012 Apr 18. Immunol Allergy Clin North Am. 2012. PMID: 22560145 Review.

• Bullous autoimmune dermatoses.

  Hofmann SC, Juratli HA, Eming R. Hofmann SC, et al. J Dtsch Dermatol Ges. 2018 Nov;16(11):1339-1358. doi: 10.1111/ddg.13688. J Dtsch Dermatol Ges. 2018. PMID: 30395395

Cited by

• [Pemphigus. Model disease for targeted therapy].

  Eming R. Eming R. Hautarzt. 2015 Aug;66(8):574-82. doi: 10.1007/s00105-015-3656-3. Hautarzt. 2015. PMID: 26231572 Review. German.

• Autoimmune blistering disorders in the setting of human immunodeficiency virus infection.

  Min MS, Damstetter E, Chen AYY. Min MS, et al. Int J Womens Dermatol. 2018 Jun 11;4(3):159-165. doi: 10.1016/j.ijwd.2018.02.002. eCollection 2018 Sep. Int J Womens Dermatol. 2018. PMID: 30175218 Free PMC article. Review.

• Intravenous immunoglobulin as clinical immune-modulating therapy.

  Gilardin L, Bayry J, Kaveri SV. Gilardin L, et al. CMAJ. 2015 Mar 3;187(4):257-264. doi: 10.1503/cmaj.130375. Epub 2015 Feb 9. CMAJ. 2015. PMID: 25667260 Free PMC article. Review. No abstract available.

• A Case of Severe Bullous Dermatitis With Mixed Bullous Pemphigoid and Pemphigus Vulgaris Cutaneous Manifestations.

  Burns RD, Vetos D, Muraga R. Burns RD, et al. Cureus. 2021 Dec 15;13(12):e20433. doi: 10.7759/cureus.20433. eCollection 2021 Dec. Cureus. 2021. PMID: 35047270 Free PMC article.

• Changes in Hemoglobin Concentrations Post-immunoglobulin Therapy in Patients with Kawasaki Disease: A Population-Based Study Using a Claims Database in Japan.

  Takeuchi M, Ito S, Nakamura M, Kawakami K. Takeuchi M, et al. Paediatr Drugs. 2018 Dec;20(6):585-591. doi: 10.1007/s40272-018-0316-y. Paediatr Drugs. 2018. PMID: 30345488

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal